These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28341930)

  • 1. Clinical Utility of Cxbladder for the Diagnosis of Urothelial Carcinoma.
    Darling D; Luxmanan C; O'Sullivan P; Lough T; Suttie J
    Adv Ther; 2017 May; 34(5):1087-1096. PubMed ID: 28341930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of a non-invasive urine test for risk assessing patients with no obvious benign cause of hematuria: a physician-patient real world data analysis.
    Lough T; Luo Q; Luxmanan C; Anderson A; Suttie J; O'Sullivan P; Darling D
    BMC Urol; 2018 Mar; 18(1):18. PubMed ID: 29523118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician-Patient Real-World Clinical Data Analysis.
    Lough T; Luo Q; O'Sullivan P; Chemaslé C; Stotzer M; Suttie J; Darling D
    Oncol Ther; 2018 Jun; 6(1):73-85. PubMed ID: 32700139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary Analysis of
    Lotan Y; Raman JD; Konety B; Daneshmand S; Schroeck F; Shariat SF; Black P; de Lange M; Asroff S; Goldfischer E; Efros M; Chong KT; Huang E; Chua HL; Wu QH; Yeow S; Lau W; Yong J; Eng M
    J Urol; 2023 Apr; 209(4):762-772. PubMed ID: 36583640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
    O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
    J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.
    Konety B; Shore N; Kader AK; Porten S; Daneshmand S; Lough T; Lotan Y
    Eur Urol; 2019 Aug; 76(2):238-243. PubMed ID: 31103391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
    Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
    BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients.
    Tyson MD; Abouassaly R; Durant A; Smith AB; Seemann K; Shoskes DA
    Urol Pract; 2024 Jan; 11(1):54-60. PubMed ID: 37914255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma.
    Lotan Y; OʼSullivan P; Raman JD; Shariat SF; Kavalieris L; Frampton C; Guilford P; Luxmanan C; Suttie J; Crist H; Scherr D; Asroff S; Goldfischer E; Thill J; Darling D
    Urol Oncol; 2017 Aug; 35(8):531.e15-531.e22. PubMed ID: 28366272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma.
    Raman JD; Kavalieris L; Konety B; Porten S; Daneshmand S; Lotan Y; Loo R
    J Urol; 2021 Dec; 206(6):1380-1389. PubMed ID: 34348469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria: The Safe Testing of Risk for Asymptomatic Microhematuria Trial.
    Lotan Y; Daneshmand S; Shore N; Black P; Scarpato KR; Patel A; Lough T; Shoskes DA; Raman JD
    J Urol; 2024 Jul; 212(1):41-51. PubMed ID: 38700731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.
    Kavalieris L; O'Sullivan P; Frampton C; Guilford P; Darling D; Jacobson E; Suttie J; Raman JD; Shariat SF; Lotan Y
    J Urol; 2017 Jun; 197(6):1419-1426. PubMed ID: 27986532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.
    Krabbe LM; Woldu SL; Shariat SF; Lotan Y
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1189-1199. PubMed ID: 27696932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets.
    Breen V; Kasabov N; Kamat AM; Jacobson E; Suttie JM; O'Sullivan PJ; Kavalieris L; Darling DG
    BMC Med Res Methodol; 2015 May; 15():45. PubMed ID: 25962444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
    Guo RQ; Xiong GY; Yang KW; Zhang L; He SM; Gong YQ; He Q; Li XY; Wang ZC; Bao ZQ; Li XS; Zhang K; Zhou LQ
    Urol Oncol; 2018 Jul; 36(7):342.e15-342.e23. PubMed ID: 29706459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Oncuria™, a Multiplexed Liquid Biopsy for the Non-Invasive Detection of Bladder Cancer-A Pilot Study.
    Murakami K; Pagano I; Furuya H; Daskivich T; Mori D; Rosser CJ
    Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic tests in urology: urine cytology.
    Lavallée LT; Fergusson D; Dahm P; Scales CD; Witiuk K; Breau RH
    BJU Int; 2012 Dec; 110(11 Pt C):E789-91. PubMed ID: 23106855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder cancer in Sri Lanka: experience from a tertiary referral center.
    Goonewardena SA; De Silva WA; De Silva MV
    Int J Urol; 2004 Nov; 11(11):969-72. PubMed ID: 15509199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.